Successful nedaplatin desensitization therapy in a patient with platinum-sensitive recurrent ovarian cancer: A case report and literature review

Kokabu, Tetsuya; Aoyama, Kohei; Tarumi, Yosuke; Kataoka, Hideki; Yoriki, Kaori; Mori, Taisuke

doi:10.1016/j.gore.2022.101065

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The great advantage of the drug is the lack of nephrotoxicity, and its cytotoxic effect is similar to that of carboplatin [85]. Clinical studies have shown that nedaplatin is highly effective in the treatment of ovarian cancer recurrences previously treated with cisplatin [85,94].…”

Section: Designing Of Cisplatin Analogsmentioning

confidence: 99%

Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions

Zoń

Bednarek

2023

IJMS

View full text Add to dashboard Cite

Cisplatin is one of the most commonly used anticancer drugs worldwide. It is mainly used in the treatment of ovarian cancer, but also used in testicular, bladder and lung cancers. The significant advantage of this drug is the multidirectional mechanism of its anticancer action, with the most important direction being damaging the DNA of cancer cells. Unfortunately, cisplatin displays a number of serious disadvantages, including toxicity to the most important organs, such as kidneys, heart, liver and inner ear. Moreover, a significant problem among patients with ovarian cancer, treated with cisplatin, is the development of numerous resistance mechanisms during therapy, including changes in the processes of cellular drug import and export, changes in the DNA damage repair mechanisms, as well as numerous changes in the processes of apoptosis and autophagy. Due to all of the mentioned problems, strategies to increase the effectiveness of cisplatin in the treatment of ovarian cancer are intensively sought. The most important strategy includes the development of less toxic cisplatin analogs. Another important direction is combination therapy, involving the simultaneous use of cisplatin with different anticancer drugs, substances derived from plants, temperature or radiotherapy. Many years of observations accompanying the presence of cisplatin in the therapy made it possible to provide a series of verifiable, statistically significant data, but also to show how, over time, with the new information and scientific discoveries, it is possible to describe and understand the therapeutic problems observed in practice, such as the acquisition of drug resistance by tumor cells or induction of changes in the tumor microenvironment. According to the authors, confronting what we knew so far with what new trends offer has a profound meaning. This paper presents information on the history of cisplatin and describes the molecular mechanisms of its action and the development of resistance by cancer cells. In addition, our goal was to highlight a number of therapeutic strategies to increase the effectiveness of cisplatin in the treatment of ovarian cancer, as well as to identify methods to eliminate problems associated with the use of cisplatin.

show abstract

Section: Designing Of Cisplatin Analogsmentioning

confidence: 99%

Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions

Zoń

Bednarek

2023

IJMS

View full text Add to dashboard Cite

show abstract

Carboplatin/nedaplatin

2023

Reactions Weekly

View full text Add to dashboard Cite

Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data

Li,

Yin

2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundTo examine the value of five-step platinum desensitization therapy in epithelial ovarian cancerMethodsA retrospective study was conducted on the high-grade serous adenocarcinoma of the ovary (HGSAO) patients who developed a platinum allergy during treatment and received desensitization therapy between January, 2016 and December, 2020. The logistic-regression was adopted to analyze the relationship between platinum desensitization therapy and prognosis in HGSAO patients.Results92 HGSAO patients were included in the study. Among these, 35 patients (38.0%) experienced mild allergic reactions, 51 (55.4%) experienced moderate allergic reactions, and 6 (6.5%) experienced severe allergic reactions. The desensitization therapy was successful in 86 patients (93.5%). Six patients had desensitization failure, of which five experienced severe allergic reactions during desensitization. The logistic-regression analysis revealed no significant correlation between platinum desensitization therapy and progression-free survival (PFS) or overall survival (OS) of patients (P < 0.05). However, the subgroup analysis demonstrated that the success or failure of platinum desensitization therapy significantly impacted the OS of patients who were platinum-sensitive recurrence. The patients who had successful desensitization therapy had a superior OS.ConclusionFive-step platinum desensitization therapy has potential application value in patients who were platinum-sensitive recurrence after first-line treatment but may bear the risk of severe allergic reactions.

show abstract

Successful nedaplatin desensitization therapy in a patient with platinum-sensitive recurrent ovarian cancer: A case report and literature review

Cited by 3 publications

References 15 publications

Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions

Cisplatin in Ovarian Cancer Treatment—Known Limitations in Therapy Force New Solutions

Carboplatin/nedaplatin

Platinum desensitization therapy and its impact on the prognosis of ovary high-grade serous adenocarcinoma: a real world-data

Contact Info

Product

Resources

About